Research programme: antibacterials - AriBio

Drug Profile

Research programme: antibacterials - AriBio

Alternative Names: AR 1003; AR 1004

Latest Information Update: 13 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AriBio
  • Class Antibacterials; Quinolones
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pneumonia; Sepsis

Most Recent Events

  • 01 Jun 2016 Preclinical trials in Pneumonia in South Korea (unspecified route)
  • 01 Jun 2016 Preclinical trials in Sepsis in South Korea (unspecified route)
  • 01 Jun 2016 AriBio plans a clinical trial for Sepsis in USA and South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top